Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1P01CA214278, R01CA226983)
Received: 18 January 2022
Accepted: 2 March 2022
First Online: 19 April 2022
: C.H.J. has received grant support from Novartis, and has patents related to CAR therapy with royalties paid from Novartis to the University of Pennsylvania. C.H.J. is also a scientific co-founder and holds equity in Capstan Therapeutics and Tmunity Therapeutics. C.H.J. serves on the board of AC Immune and is a scientific advisor to Alaunos, BluesphereBio, Cabaletta, Carisma, Cartography, Cellares, Cellcarta, Celldex, Danaher, Decheng, ImmuneSensor, Poseida, Verismo, Viracta, and WIRB-Copernicus group.